0001711754
false
0001711754
2023-11-01
2023-11-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): November 1,
2023
|
INMUNE BIO INC. |
|
|
(Exact name of registrant as specified in charter) |
|
Nevada |
|
001-38793 |
|
47-5205835 |
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
of incorporation) |
|
|
|
Identification No.) |
225 NE Mizner Blvd., Suite 640
Boca Raton, Florida 33432
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per shares |
|
INMB |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results
of Operations and Financial Condition.
On November 1, 2023,
INmune Bio Inc. (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended
September 30, 2023 and providing a business update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
The information in this
Current Report, including the exhibits hereto, is being furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2)
of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not
be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission,
whether made before or after the date of this report, regardless of any general incorporation language in such filing (or any reference
to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INMUNE BIO INC. |
|
|
Date: November 1, 2023 |
By: |
/s/ David Moss |
|
|
David Moss |
|
|
Chief Financial Officer |
2
Exhibit 99.1
INmune Bio
Inc. Announces Third Quarter 2023 Results and Provides Business Update
Company to Host Conference Call Today, November
1, at 4:30pm ET
BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE)
-- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing
treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter
ended September 30, 2023 and provides a business update.
Q3 2023 Corporate Highlights:
DN-TNF Platform Highlights (XPro™):
| ● | AD02 blinded randomized program in patients with
Early Alzheimer’s Disease (AD) received authorization of its Clinical Trial Application (CTA) by the Medicines and Healthcare products
Regulatory Agency (MHRA) to initiate a Phase II trial in Early Alzheimer’s disease (AD) with XPro™. The U.K. CTA is part
of the Company’s international clinical development strategy for XPro™ in patients with early AD. The trial is also enrolling
patients in Australia and Canada. Recruitment of the trial is increasing and the company anticipates results of the Phase II program
towards the end of 2024. Discussions with the FDA remain ongoing, and we continue to believe the clinical hold will be lifted before the
end-of-year 2023. |
| ● | Announced expansion of novel MRI biomarker data
to include grey matter. Grey matter, the portion of the brain containing nerve cell bodies, has historically been the focus of Alzheimer’s
disease research and drug development. Previous MRI biomarker analysis from patients receiving XPro™ for treatment of AD has demonstrated
early changes in white matter that predict presence of neuroinflammation and response to XPro™ therapy. The new data, reported at
the annual Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands in July, demonstrates improvement in
grey matter microstructure in patients with AD. The data confirm that neuroinflammation affects microstructure of both white and gray
matter of the brain. These changes can be quantified in a “virtual brain biopsy”. Treatment with XPro™ resulted in improvements
in both white and grey matter microstructural elements that may predict improvements in cognition. The data further validates the biomarker
package associated with the on-going Phase II trial in patients with Early AD. |
| ● | The findings presented at CTAD demonstrated effective
use of home EEG in patients receiving XPRO for treatment of Alzheimer’s disease. Changes in P300 and other EEG measures were seen
after treatment with XPRO. These data add to the biomarker package that can be used to develop XPRO for Alzheimer’s disease and
other types of dementia. |
| ● | Data was presented at the 16th European
Meeting on Glial Cells in Health and Disease in Berlin showing XPro™ promotes remyelination in animal studies of MS. These data
focused on how XPRO promotes microglial cells to phagocytize myelin debris. Removal of myelin debris is a key step in promoting oligodendrocyte
function. Oligodendrocytes produce myelin. These data are consistent with the remyelination that is seen in humans with AD after treatment
with XPro. To our knowledge, XPRO is maybe the only drug therapy to demonstrate remyelination in humans. Therapies that promote remyelination
may be needed to effectively treat many neurodegenerative diseases including Alzheimer’s disease. |
| ● | Presented preclinical data at 38th Society
of Immunotherapy for Cancer showing INB03 is an innate immune checkpoint inhibitor. INB03 neutralizes sTNF, repolarizing tumor-protecting
M2 macrophages to M1 anti-tumor macrophages, downregulates expression of SIRPα, and enhances antibody dependent cellular phagocytosis.
SIRPα, signal-regulatory protein expressed on macrophages, is part of the SIRPa–CD47 “don’t eat me” pathway,
a phagocytosis checkpoint in macrophages and other innate immune cells. |
INKmune™ Platform:
| ● | Remain on track to launch Phase I/II open label
trial using INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) after clearance of the IND by the Food & Drug
Administration (FDA) in May. The trial is expected to enroll the first of 30 patients before end-of-year 2023. Patients will receive three
infusions of INKmune™ as out-patient treatment during the six-month trial. Three doses of INKmune™ are being tested
in a modified Bayesian Phase I/II trial that uses biomarkers to determine immunologic and tumor response to INKmune. |
| ● | LAUREL, the INKmune™ trial in high risk
MDS and AML has shipped INKmune™ to the third clinical site in Athens, Greece. The site is screening patients and expects to
treat their first patient imminently, which will close the first dose cohort. Changing management of high risk MDS patients in the UK
has resulted in screen failures. The cause of these screen failures has been identified and addressed to help increase recruiting of patient
into |
| ● | LAUREL. The Company received regulatory approval
on October 20th for the revised enrollment criteria to increase the pool of potential patients to drive recruitment. |
| ● | Pre-clinical work has confirmed in vitro activity of INKmune™-primed
NK cells in nasopharyngeal cancer and renal cell cancers and non-dilutive funding is being sought to progress to trial in Q3-4 2024. |
| ● | Received a written opinion for the international patent application titled,
“HUMAN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINE & APPLICATIONS FOR TREATING CANCER,” an examiner from the International
Search Authority at the United States Patent & Trademark Office (USPTO), authorized by the World Intellectual Property Organization
(WIPO) under the Patent Cooperation Treaty (PCT), issued a favorable patentability opinion with respect to novelty, inventive step and
industrial applicability of all claims and concluding that the application contains patentable subject matter. The application discloses
and claims the novel INB16 cell line on deposit with the American Type Culture Collection (ATCC), as well as compositions comprising replication
incompetent INB16 cells (“INKmune™”) and methods of treating cancer in patients by administering INKmune™. |
Upcoming Events and Milestones:
| ● | On track to have FDA lift clinical hold on the
use of XPRO to treat patients with CNS disease in the US by end-of-year 2023. |
| ● | Top-line results for the Phase II XPro™ trial
for treatment of patients with early Alzheimer’s disease with biomarkers of neuroinflammation are expected end-of-year 2024. |
| ● | Initiate a Phase II trial of XPro™ in
patients with Treatment-Resistant Depression upon resolution of the ongoing FDA manufacturing review. |
| ● | Webinar on using XPro™ to promote remyelination
in neurodegenerative disease. |
| ● | Additional open-label Phase I trial data of INKmune™
in high-risk MDS/AML in 2023. |
| ● | Initiation of open-label Phase I/II trial in
prostate cancer in Q4 2023 with patient data expected during 2024. |
Financial Results for the Quarter Ended September
30, 2023:
| ● | Net loss attributable to common stockholders
for the quarter ended September 30, 2023, was approximately $8.6 million, compared to approximately $7.7 million during the quarter ended
September 30, 2022. |
| ● | Research and development expenses totaled approximately
$6.0 million for the quarter ended September 30, 2023, compared to approximately $5.2 million during the quarter ended September 30, 2022. |
| ● | General and administrative expense were approximately
$2.6 million for the quarter ended September 30, 2023, compared to approximately $2.4 million during the quarter ended September 30, 2022. |
| ● | Other expense was approximately $0.0 million
for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022. |
| ● | As of September 30, 2023, the Company had cash
and cash equivalents of approximately $41.8 million. |
| ● | As of November 1, 2023, the Company had approximately
18.0 million common shares outstanding. |
Earnings Call Information
To participate in this event, dial approximately
5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.
Date: November 1, 2023
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-877-407-0784
Participant Dial-in (international): 1-201-689-8560
Conference ID: 13741726
A live audio webcast of the call can be accessed
using this link or clicking here:
https://viavid.webcasts.com/starthere.jsp?ei=1637274&tp_key=e7f5108b08
A transcript will follow approximately 24
hours from the scheduled call. A replay will also be available through November 8 by dialing 1-844-512-2921 or 1-412-317-6671 (international)
and entering PIN no. 13741726.
About XPro™
XPro™ is a next-generation inhibitor
of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that
it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro™ could have potential substantial
beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting
neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.
About INKmune™
INKmune™ is a pharmaceutical-grade,
replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to
convert the cancer patient’s resting NK cells into tumor killing memory-like NK cells (mlNK cells). INKmune™ treatment
converts the patient’s own NK cells into mlNK cells. In patients, INKmune™ primed tumor killing NK cells persist for more
than 100 days and function in the hypoxic TME because due to upregulated nutrient and mitochondrial survival proteins. INKmune™
is a patient friendly that does not require pre-medication, conditioning or additional cytokine therapy given to the patients. INKmune™
is easily transported, stored and delivered to the patient by a simple intravenous infusion as an out-patient. INKmune™ is tumor
agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal
and nasopharyngeal cancer. INKmune™ is treating patients in an open label Phase I trial in high-MDS/AML in the UK and Europe.
The company plans an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US this year.
About INmune Bio Inc.
INmune Bio Inc. is a publicly
traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight
disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product
platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a
mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™),
Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming
Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with
cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic
and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there
is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on
current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances
may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™,
XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved
by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the
FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ
materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability
to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations
and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and
described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual
Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company
assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the
date of this release.
About INmune Bio Inc.
INmune Bio Inc. is
a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune
system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor
(DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction
and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™),
Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming
Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with
cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic
and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there
is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on
current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances
may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™,
XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved
by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the
FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ
materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability
to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations
and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and
described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual
Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company
assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the
date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720
info@inmunebio.com
Investor Contact:
Jason Nelson
Core IR
(516) 842-9614 x-823
The following tables summarize our results
of operations for the periods indicated:
INMUNE BIO INC.
CONDENSED CONSOLIDATED
BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
| |
September 30, 2023 | | |
December 31, 2022 | |
ASSETS | |
| | |
| |
CURRENT ASSETS | |
| | |
| |
Cash and cash equivalents | |
$ | 41,813 | | |
$ | 52,153 | |
Research and development tax credit receivable | |
| 2,087 | | |
| 8,099 | |
Other tax receivable | |
| 176 | | |
| 362 | |
Prepaid expenses and other current assets | |
| 1,535 | | |
| 4,027 | |
Prepaid expenses – related party | |
| - | | |
| 34 | |
TOTAL CURRENT ASSETS | |
| 45,611 | | |
| 64,675 | |
| |
| | | |
| | |
Operating lease – right of use asset | |
| 444 | | |
| 507 | |
Other assets | |
| 129 | | |
| 99 | |
Acquired in-process research and development intangible assets | |
| 16,514 | | |
| 16,514 | |
| |
| | | |
| | |
TOTAL ASSETS | |
$ | 62,698 | | |
$ | 81,795 | |
| |
| | | |
| | |
LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable and accrued liabilities | |
$ | 3,675 | | |
$ | 5,206 | |
Accounts payable and accrued liabilities – related parties | |
| 79 | | |
| 9 | |
Deferred liabilities | |
| 496 | | |
| 616 | |
Current portion of long-term debt | |
| 10,000 | | |
| 5,000 | |
Operating lease, current liabilities | |
| 106 | | |
| 87 | |
TOTAL CURRENT LIABILITIES | |
| 14,356 | | |
| 10,918 | |
| |
| | | |
| | |
Long-term debt, net | |
| 2,376 | | |
| 9,697 | |
Long-term operating lease liabilities | |
| 430 | | |
| 526 | |
Accrued liability – long-term | |
| 804 | | |
| 550 | |
TOTAL LIABILITIES | |
| 17,966 | | |
| 21,691 | |
| |
| | | |
| | |
COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| |
| | | |
| | |
Redeemable common stock, $0.001 par value; 75,697 and 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| 799 | | |
| - | |
| |
| | | |
| | |
STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding | |
| - | | |
| - | |
Common stock, $0.001 par value, 200,000,000 shares authorized, 17,945,995 shares issued and outstanding | |
| 18 | | |
| 18 | |
Additional paid-in capital | |
| 157,264 | | |
| 151,799 | |
Accumulated other comprehensive loss | |
| (735 | ) | |
| (699 | ) |
Accumulated deficit | |
| (112,614 | ) | |
| (91,014 | ) |
TOTAL STOCKHOLDERS’ EQUITY | |
| 43,933 | | |
| 60,104 | |
| |
| | | |
| | |
TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY | |
$ | 62,698 | | |
$ | 81,795 | |
INMUNE BIO INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)
| |
For the Three Months Ended September 30, | | |
For the Nine Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
REVENUE | |
$ | 43 | | |
$ | 98 | | |
$ | 127 | | |
$ | 277 | |
| |
| | | |
| | | |
| | | |
| | |
OPERATING EXPENSES | |
| | | |
| | | |
| | | |
| | |
General and administrative | |
| 2,586 | | |
| 2,382 | | |
| 7,223 | | |
| 6,929 | |
Research and development | |
| 5,985 | | |
| 5,159 | | |
| 14,266 | | |
| 13,657 | |
Total operating expenses | |
| 8,571 | | |
| 7,541 | | |
| 21,489 | | |
| 20,586 | |
| |
| | | |
| | | |
| | | |
| | |
LOSS FROM OPERATIONS | |
| (8,528 | ) | |
| (7,443 | ) | |
| (21,362 | ) | |
| (20,309 | ) |
| |
| | | |
| | | |
| | | |
| | |
OTHER EXPENSE, NET | |
| (35 | ) | |
| (282 | ) | |
| (238 | ) | |
| (1,157 | ) |
| |
| | | |
| | | |
| | | |
| | |
NET LOSS | |
$ | (8,563 | ) | |
$ | (7,725 | ) | |
$ | (21,600 | ) | |
$ | (21,466 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per common share – basic and diluted | |
$ | (0.48 | ) | |
$ | (0.43 | ) | |
$ | (1.20 | ) | |
$ | (1.20 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding – basic and diluted | |
| 18,008,295 | | |
| 17,945,995 | | |
| 17,966,990 | | |
| 17,921,036 | |
| |
| | | |
| | | |
| | | |
| | |
COMPREHENSIVE LOSS | |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (8,563 | ) | |
$ | (7,725 | ) | |
$ | (21,600 | ) | |
$ | (21,466 | ) |
Other comprehensive loss – foreign currency translation | |
| (23 | ) | |
| (441 | ) | |
| (36 | ) | |
| (1,143 | ) |
Total comprehensive loss | |
$ | (8,586 | ) | |
$ | (8,166 | ) | |
$ | (21,636 | ) | |
$ | (22,609 | ) |
INMUNE BIO INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| |
For the Nine Months Ended September 30, | |
| |
2023 | | |
2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
Net loss | |
$ | (21,600 | ) | |
$ | (21,466 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Stock-based compensation | |
| 5,489 | | |
| 5,361 | |
Accretion of debt discount | |
| 179 | | |
| 171 | |
Impairment of operating lease – right of use asset | |
| - | | |
| 89 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Research and development tax credit receivable | |
| 6,012 | | |
| 496 | |
Other tax receivable | |
| 186 | | |
| 477 | |
Prepaid expenses | |
| 2,492 | | |
| (2,321 | ) |
Prepaid expenses – related party | |
| 34 | | |
| (109 | ) |
Other assets | |
| (30 | ) | |
| - | |
Accounts payable and accrued liabilities | |
| (1,531 | ) | |
| (268 | ) |
Accounts payable and accrued liabilities – related parties | |
| 70 | | |
| (72 | ) |
Deferred liabilities | |
| (120 | ) | |
| 304 | |
Accrued liability – long-term | |
| 254 | | |
| 264 | |
Operating lease liabilities | |
| (14 | ) | |
| 83 | |
Net cash used in operating activities | |
| (8,579 | ) | |
| (16,991 | ) |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Net proceeds from sale of common stock | |
| 775 | | |
| 699 | |
Repayments of debt | |
| (2,500 | ) | |
| - | |
Net proceeds from the exercise of warrants | |
| - | | |
| 30 | |
Net cash (used in) provided by financing activities | |
| (1,725 | ) | |
| 729 | |
| |
| | | |
| | |
Impact on cash from foreign currency translation | |
| (36 | ) | |
| (1,143 | ) |
| |
| | | |
| | |
NET DECREASE IN CASH AND CASH EQUIVALENTS | |
| (10,340 | ) | |
| (17,405 | ) |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | |
| 52,153 | | |
| 74,810 | |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | |
$ | 41,813 | | |
$ | 57,405 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: | |
| | | |
| | |
Cash paid for income taxes | |
$ | - | | |
$ | - | |
Cash paid for interest expense | |
$ | 1,394 | | |
$ | 962 | |
8
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
Von Mai 2023 bis Mai 2024